Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28625302 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL667744 | 1.00 | — | — | |
| Acetic Acid SCHEMBL29087070 | 1.00 | — | — | |
| Acetic Acid SCHEMBL8930581 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL11224118 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL28667600 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL11290705 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL3151584 | 1.00 | — | — | |
| Acetic Acid SCHEMBL11226455 | 1.00 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL8921965 | 1.00 | FFAR3 (0.88) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637826-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4634231-A1 | ANTI-MUC-16 ANTIBODIES AND METHODS OF USE THEREOF | University of Saskatchewan (CA) | 2025-10-22 | — | — | EP | claimed |
| EP-3548096-B1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2024133780-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-4389150-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-26 | — | — | EP | claimed |
| WO-2024124337-A1 | ANTI-MUC-16 ANTIBODIES AND METHODS OF USE THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2024-06-20 | — | — | WO | claimed |
| WO-2023034701-A1 | HIF-1 PROMOTING COMPOUNDS FOR TREATING AUTONOMIC SKIN DYSFUNCTION FOLLOWING SPINAL CORD INJURY | TAUTONA GROUP IP HOLDING COMPANY, L.L.C. (US) | 2023-03-09 | — | — | WO | claimed |
| JP-1228996-A | — | — | None | — | — | JP | disclosed |
| US-12605461-B2 | Hydrogel compositions and uses thereof | Shoichet, Molly Sandra (CA) | 2026-04-21 | — | — | US | disclosed |
| EP-4637826-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634231-A1 | ANTI-MUC-16 ANTIBODIES AND METHODS OF USE THEREOF | University of Saskatchewan (CA) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312270-A1 | READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS | AMNEAL EU, LIMITED (IE) | 2025-10-09 | — | — | US | disclosed |
| US-20250025409-A1 | READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONS | AMNEAL EU, LIMITED (IE) | 2025-01-23 | — | — | US | disclosed |
| EP-1527049-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004014860-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | WO | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0942906-A2 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998030558-A2 | TRICYCLIC COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0577675-A1 | CONTRAST MEDIA | NYCOMED SALUTAR, INC. (US) | 1994-01-12 | — | — | EP | disclosed |
| JP-H01228996-A | PREPARATION OF N-PHOSPHONO-METHYL-IMINO-DIACETIC ACID | NITROKEMIA IPARTELEPEK | 1989-09-12 | — | — | JP | disclosed |